SURGICAL SITE INFECTION (SSI) SYNOPSIS, INCLUDING MODIFIABLE AND NON-MODIFIABLE RISK FACTORS Estimated 45,000 SSIs occur annually in Australia leading to approximately 900 deaths.
Reducing surgical site infections (SSIs) involves a combination of measures before, during, and after surgery. These include preoperative measures, with preoperative antibiotics, skin preparation and hair removal.
Intraoperative measures including deploying sterile and proper surgical technique, including maintaining normothermia or body temperature within ranges that optimise immune function and wound healing.
Postoperative measures include surgical wound management, using appropriate dressing changes, and anti-bacterial sutures. The mobilisation of the patient is continued to improve circulation and promote healing, as well as the monitoring and surveillance of signs of infection.
Some of these measures are discussed by Professor Philip Russo, a healthcare researcher and the Director of Research at Nursing and Midwifery at Monash University in Melbourne.
Professor Russo has dedicated the last decade to studying healthcare-associated infection and infection prevention and control. His focus has been on surgical site infections, which are common in hospital settings.
He talks about surgical site infections classified as either superficial, involving only the subcutaneous tissue, or deep, which may involve muscle, bone, or organs. These infections occur after a surgical procedure, manifesting as redness, soreness, and fever around the surgical site. While superficial infections are generally easier to treat with a short course of antibiotics and are often managed outside the hospital, deep and organ space infections are more serious and can be life-threatening. They often require long courses of antimicrobial therapy and may necessitate additional surgical intervention, leading to extended hospital stays and increased morbidity and mortality.
Talking to the Australian Health Journal, Professor Russo states there is a particular concern in joint operations, such as hip or knee replacements, as infections in these areas can have severe consequences, including the removal of the infected joint, prolonged treatment, and significant costs for both hospitals and patients. Despite the substantial impact of surgical site infections, Australia lacks a national surveillance program for these infections, making it challenging to obtain accurate data. However, an estimate suggests that around 45,000 surgical site infections occur annually in Australia, resulting in approximately 900 deaths.
To better understand the prevalence of surgical site infections, Professor Russo and his team conducted a point prevalence survey in 19 acute large hospitals across Australia. The survey revealed that approximately 10% of patients had an infection, with surgical site infections accounting for around 28% of these cases, making them the most common type of infection found in adults in acute care hospitals in 2017-2018.
Professor Russo also highlights various risk factors that contribute to the development of surgical site infections, including non-modifiable factors such as age, gender, and immune status, as well as modifiable factors like diabetes, obesity, and tobacco use. By addressing these risk factors before and during surgery, the likelihood of infection can be reduced.
Through his research, Professor Russo aims to raise awareness about the significant impact of surgical site infections and the importance of implementing preventive measures to reduce their occurrence and improve patient outcomes.
You Might also like
-
Elevating Professional Standards in the Medtech and Pharmaceutical Sector
ARCS Australia Ltd, the peak body representing professionals in the MedTech and Pharmaceutical sector, this week announced a series of significant changes at its annual conference.
Dr Tim Boyle, CEO of ARCS Australia Ltd speaking to Australian Health Journal says, “These initiatives are central to strategy to build professionalism within the sector, increase capability and enhance the professional standing of its members.”
-
30 years on, Viertel Foundation legacy continues
One of Australia’s largest charitable foundations, the Sylvia and Charles Viertel Charitable Foundation, is celebrating three decades of transforming Australian healthcare – with more than $90 million invested in medical research and a legacy of breakthroughs that are saving lives. Viertel Fellowships support some of Australia’s best and brightest researchers and clinicians, with 70 Fellowships awarded to date.
-
Foundation outlines breast cancer research strategy
Australian Health Journal met with Associate Professor Cleola Anderiesz, CEO of the National Breast Cancer Foundation to hear of the new 5 year Pink Horizon research strategy. Those with lived experience of breast cancer, along with researchers, clinicians, and other funding organisations, have contributed to the development of the foundation’s new five-year Pink Horizon research strategy. This ambitious plan aims to invest $125 million to accelerate research efforts towards the vision of ending deaths from breast cancer.